ES2909557T3 - Utilización de la pridopidina para el tratamiento del síndrome de Rett - Google Patents

Utilización de la pridopidina para el tratamiento del síndrome de Rett Download PDF

Info

Publication number
ES2909557T3
ES2909557T3 ES17851614T ES17851614T ES2909557T3 ES 2909557 T3 ES2909557 T3 ES 2909557T3 ES 17851614 T ES17851614 T ES 17851614T ES 17851614 T ES17851614 T ES 17851614T ES 2909557 T3 ES2909557 T3 ES 2909557T3
Authority
ES
Spain
Prior art keywords
pridopidine
subject
composition
administered
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17851614T
Other languages
English (en)
Spanish (es)
Inventor
Michal Geva
Ralph Laufer
Michael Hayden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prilenia Neurotherapeutics Ltd
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Application granted granted Critical
Publication of ES2909557T3 publication Critical patent/ES2909557T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
ES17851614T 2016-09-16 2017-09-15 Utilización de la pridopidina para el tratamiento del síndrome de Rett Active ES2909557T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662395854P 2016-09-16 2016-09-16
PCT/US2017/051803 WO2018053280A1 (en) 2016-09-16 2017-09-15 Use of pridopidine for treating rett syndrome

Publications (1)

Publication Number Publication Date
ES2909557T3 true ES2909557T3 (es) 2022-05-09

Family

ID=61619744

Family Applications (2)

Application Number Title Priority Date Filing Date
ES22150695T Active ES2986807T3 (es) 2016-09-16 2017-09-15 Pridopidina para su uso en el tratamiento del síndrome de Rett
ES17851614T Active ES2909557T3 (es) 2016-09-16 2017-09-15 Utilización de la pridopidina para el tratamiento del síndrome de Rett

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES22150695T Active ES2986807T3 (es) 2016-09-16 2017-09-15 Pridopidina para su uso en el tratamiento del síndrome de Rett

Country Status (13)

Country Link
EP (2) EP3512506B1 (enExample)
JP (1) JP6977029B2 (enExample)
CN (1) CN109982686A (enExample)
AU (1) AU2017326013B2 (enExample)
BR (1) BR112019005040A2 (enExample)
CA (1) CA3036984C (enExample)
DK (2) DK3512506T3 (enExample)
ES (2) ES2986807T3 (enExample)
HU (1) HUE058314T2 (enExample)
IL (1) IL265342B2 (enExample)
MX (1) MX388845B (enExample)
PL (2) PL3512506T3 (enExample)
WO (1) WO2018053280A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014205229A1 (en) 2013-06-21 2014-12-24 IVAX International GmbH Use of high dose pridopidine for treating huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
BR112019003731A2 (pt) 2016-08-24 2019-07-16 Prilenia Therapeutics Dev Ltd aplicação de pridopidina para tratamento de distonias
JP6912574B2 (ja) 2016-08-24 2021-08-04 プリレニア ニューロセラピューティクス リミテッド 機能低下を治療するためのプリドピジンの使用
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
ES2986807T3 (es) 2016-09-16 2024-11-12 Prilenia Neurotherapeutics Ltd Pridopidina para su uso en el tratamiento del síndrome de Rett
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12357624B2 (en) 2019-02-04 2025-07-15 Prilenia Neurotherapeutics Ltd. Low dose pridopidine for Parkinson's Disease and other diseases associated with parkinsonism
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
AU2005293754B2 (en) 2004-10-13 2011-07-21 Teva Pharmaceuticals International Gmbh Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine
EA201390332A1 (ru) 2010-09-03 2013-08-30 Ивакс Интернэшнл Гмбх Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов
MX347209B (es) * 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
EA027748B1 (ru) 2012-04-04 2017-08-31 Тева Фармасьютикалз Интернэшнл Гмбх Применение придопидина в комбинации с тетрабеназином для лечения двигательных нарушений и ожирения
WO2014205229A1 (en) 2013-06-21 2014-12-24 IVAX International GmbH Use of high dose pridopidine for treating huntington's disease
HUE058288T2 (hu) 2014-01-22 2022-07-28 Prilenia Neurotherapeutics Ltd Pridopidin módosított hatóanyag-leadású készítményei
WO2016138135A1 (en) * 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
EP3590512A1 (en) * 2015-02-25 2020-01-08 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat epilepsy
ES2986807T3 (es) 2016-09-16 2024-11-12 Prilenia Neurotherapeutics Ltd Pridopidina para su uso en el tratamiento del síndrome de Rett

Also Published As

Publication number Publication date
BR112019005040A2 (pt) 2019-07-16
AU2017326013B2 (en) 2020-12-24
MX388845B (es) 2025-03-20
EP3512506A4 (en) 2020-05-27
IL265342B2 (en) 2023-06-01
CA3036984A1 (en) 2018-03-22
EP3512506A1 (en) 2019-07-24
CA3036984C (en) 2023-07-18
ES2986807T3 (es) 2024-11-12
AU2017326013A1 (en) 2019-04-11
JP2019532926A (ja) 2019-11-14
EP4005570B1 (en) 2024-05-15
DK4005570T3 (da) 2024-08-19
WO2018053280A1 (en) 2018-03-22
CN109982686A (zh) 2019-07-05
IL265342A (en) 2019-05-30
HUE058314T2 (hu) 2022-07-28
EP4005570A1 (en) 2022-06-01
PL4005570T3 (pl) 2024-09-23
PL3512506T3 (pl) 2022-05-30
EP3512506B1 (en) 2022-01-26
JP6977029B2 (ja) 2021-12-08
MX2019003069A (es) 2019-09-02
DK3512506T3 (da) 2022-04-19

Similar Documents

Publication Publication Date Title
ES2909557T3 (es) Utilización de la pridopidina para el tratamiento del síndrome de Rett
CN102065897B (zh) 基于磺胺异噁唑的组合物用于制备治疗阿茨海默病的药物的应用
US20190247333A1 (en) Method of reduction in convulsive seizure frequency
JP2020535228A (ja) 患者集団中のけいれん発作の数および頻度の低減におけるフェンフルラミン製剤の使用法
JP2012528818A (ja) Cmt及び関連障害を処置するための新たな組成物
AU2018383098B2 (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
US20160193231A1 (en) Rett syndrome and treatments therefore
US10113171B2 (en) Methods for improving cognitive function via modulation of quinone reductase 2
US20210393591A1 (en) Treatments for charcot-marie-tooth disease
US20240398778A1 (en) Use of pridopidine for treating rett syndrome
US20230414596A1 (en) Use of pridopidine and analogs for treating rett syndrome
CN108601772A (zh) 用于治疗tdp-43蛋白质病的他克莫司
HK40009961B (en) Use of pridopidine for treating rett syndrome
RU2799049C2 (ru) Способы лечения изменений поведения
de Brito Pharmacological modulation of mutant ataxin-3 translation and it potential therapeutic effect in Machado Joseph disease
TW201929850A (zh) 醫藥組成物於製備預防或治療不正常乙型-澱粉樣蛋白聚集類疾病之藥物上之用途
GB2558788A (en) New therapeutic uses